Company news

Neuren Pharmaceuticals Limited news in 2017

Neuren Pharmaceuticals Limited's news releases, calls and decks from 2017, newest first.

View company

Neuren announces new US patent to be granted for NNZ-2591

December 5, 2017

Consolidation/Split - NEU

November 16, 2017

Neuren FDA meeting confirms Phase 3 plan for Rett syndrome

October 12, 2017

Presentations and publication for Rett syndrome trials

October 4, 2017

Change of Director's Interest Notice

August 29, 2017

Notice under section 708A(5)(e) of the Corporations Act

August 29, 2017

Results of Meeting

August 28, 2017

Neuren Pharmaceuticals reports 2017 half-year results

August 24, 2017

Notice of special meeting of shareholders

August 14, 2017

Neuren granted Type B Meeting with FDA for Rett syndrome

July 20, 2017

Neuren Pharmaceuticals granted Type B Meeting with FDA for Rett syndrome

July 19, 2017

Appendix 3B

July 18, 2017

Neuren secures funding for key activities for Rett syndrome

June 29, 2017

Response to ASX Price Query

June 28, 2017

Response to ASX Price Query

June 27, 2017

Trading Halt

June 27, 2017

Investor presentation, 2 June 2017

June 1, 2017

Neuren announces grant of two new patents to 2032

May 31, 2017

Notice of Annual General Meeting/Proxy Form

May 29, 2017

Response to Appendix 4C Query

May 8, 2017

Neuren receives $1 million R&D Tax Incentive

April 4, 2017

Trofinetide significant clinical benefit in Rett syndrome

March 21, 2017

Neuren completes Phase 2 trial in pediatric Rett syndrome

January 29, 2017

Decks in 2017